GlassScriptPhysician profile
Renee Tringali
NPI 1245751916
$5,365.99
in general payments reported to CMS, 2019-2025
19 companies · $3,337 in 2025
The $3,337 reported for 2025 was more than what 97% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $17.01 · 2024: $2,012 · 2025: $3,337.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,230 · Education: $119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,229.98 |
| Education | $119.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,077.19 | 2024-2025 | |
| Alkermes, INC. | $880.16 | 2024-2025 | Lybalvi, Aristada, Aristada Initio |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $784.11 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $555.45 | 2024-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Teva Pharmaceuticals USA, INC. | $474.88 | 2024-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Janssen Pharmaceuticals, INC | $268.46 | 2024-2025 | Invega Sustenna |
| Vanda Pharmaceuticals INC. | $246.49 | 2024-2025 | Fanapt |
| E.R. Squibb & Sons, L.L.C. | $240.64 | 2024-2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $183.40 | 2024-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $177.90 | 2025 | Auvelity |
| Lundbeck LLC | $122.88 | 2024-2025 | Rexulti |
| Indivior INC. | $116.27 | 2024 | Perseris |
| Tris Pharma INC | $69.65 | 2024-2025 | Dyanavel Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $52.43 | 2024 | Trintellix |
| Corium, LLC | $34.70 | 2024 | Azstarys |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $23.99 | 2025 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $23.74 | 2025 | Qelbree |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.98 | 2025 | |
| Noven Therapeutics, LLC | $16.67 | 2024 | Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Renee Tringali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.